Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
MedImmune Inc
MedImmune Inc
Activities:
Manufacturing
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
IMPACT CKD model reveals the escalating toll of chronic kidney disease
The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Isospec Analytics launches biomolecular analysis technology to identify unknown molecules
The novel technology optimises the identification process of unknown molecules compared to mass analysis
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector
The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Media
Merck is set to lead pharmaceutical licensing deals in 2018
GlobalData, a specialist data and analytics company, expects that 2018 is likely to be Merck’s year in terms of research and development collaboration
Research & Development
MedImmune and Abpro enter into a collaborative agreement for a novel bispecific antibody
Agreement to result in new spin out company, AbMed, as subsidiary of Abpro
Research & Development
AstraZeneca launches integrated genomics approach to transform drug discovery and development
The initiative includes new collaborations with Human Longevity, the Wellcome Trust Sanger Institute and The Institute for Molecular Medicine
Research & Development
AstraZeneca and Moderna Therapeutics link up to develop immuno-oncology mRNA therapeutics
Extension to an mRNA agreement for cardiovascular, metabolic and renal diseases set up in 2013
Manufacturing
Wacker Biotech grants MedImmune licence to use Esetec technology to manufacture antibody fragment
To help improve productivity and simplify the purification process
Research & Development
AstraZeneca signs third cancer deal in seven days
MedImmune enters into cancer vaccine collaboration and license agreement with Inovio Pharmaceuticals
Research & Development
Medimmune partners with the University of Sheffield to innovate cell factory technology
Partnership will create tools that could increase the yield and predictability of engineered proteins such as bispecific antibodies to treat a range of diseases
Subscribe now